{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:39:26Z","timestamp":1795081166511,"version":"4.10.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8128","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor\u00a02\u03b1 (HIF-2\u03b1)\n                    <jats:sup>1<\/jats:sup>\n                    . Here we show that monotherapy with casdatifan\u2014an orally bioavailable, potent and selective HIF-2\u03b1 inhibitor\n                    <jats:sup>2<\/jats:sup>\n                    \u2014produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC. Dose-expansion data from the ARC-20 study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05536141\" ext-link-type=\"uri\">NCT05536141<\/jats:ext-link>\n                    ) are presented, including for the 100\u2009mg once daily (QD) cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200932) and the total cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009127). Treatment discontinuation from casdatifan-related adverse events was infrequent (3%), and class-effect toxicities included anaemia and hypoxia. The confirmed objective response rates\u00a0(ORRs) were 35% (95% confidence intervals (CI)\u00a0=\u00a019\u201355%; 100\u2009mg QD) and 31% (95% CI =\u00a023\u201340%; total); median progression-free survival (PFS) was not estimable (95% CI =\u00a05.7\u2013not estimable; 100\u2009mg QD) and 12.2\u2009months (9.4\u201320.6; total). Greater maximal reductions in serum erythropoietin were associated with improved clinical outcomes, including a\u00a0higher ORR (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001), lower rates of progressive disease (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.003) and longer PFS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.006). Erythropoietin expression was restricted to cancer cells and was\u00a0significantly higher at the mRNA level in patients with clinical benefit. Concordantly, HIF-2\u03b1 protein expression and HIF-2\u03b1 expression signature were associated with prolonged PFS. Overall, our findings show that casdatifan achieves meaningful, durable responses with manageable safety. These data establish a link between on-target HIF-2\u03b1 pathway modulation, tumour biology and clinical efficacy.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-10718-x","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:43:54Z","timestamp":1782920634000},"page":"734-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Casdatifan shows durable response linked to HIF-2\u03b1 biology in kidney cancer"],"prefix":"10.1038","volume":"656","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Merch\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-3548","authenticated-orcid":false,"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley A.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3268-5426","authenticated-orcid":false,"given":"Paul","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Weeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskirat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3231-6055","authenticated-orcid":false,"given":"Angelo","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonweng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kabbarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"10718_CR1","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1074\/jbc.RA118.004902","volume":"294","author":"P Miikkulainen","year":"2019","unstructured":"Miikkulainen, P. et al. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma. J. Biol. Chem. 294, 3760\u20133771 (2019).","journal-title":"J. Biol. Chem."},{"key":"10718_CR2","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1002\/bcp.70169","volume":"91","author":"M Ghasemi","year":"2025","unstructured":"Ghasemi, M. et al. Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2\u03b1 inhibitor, in healthy participants. Br. J. Clin. Pharmacol. 91, 3366\u20133377 (2025).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10718_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala, S. A. et al. Epidemiology of renal cell carcinoma. World J. Oncol. 11, 79\u201387 (2020).","journal-title":"World J. Oncol."},{"key":"10718_CR4","unstructured":"Pandey, J. & Syed, W. Renal Cancer (StatPearls Publishing, 2025)."},{"key":"10718_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","volume":"40","author":"R Sharma","year":"2021","unstructured":"Sharma, R. et al. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J. Exp. Clin. Cancer Res. 40, 186 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10718_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","volume":"87","author":"R Barragan-Carrillo","year":"2025","unstructured":"Barragan-Carrillo, R. et al. First and second-line treatments in metastatic renal cell carcinoma. Eur. Urol. 87, 143\u2013154 (2025).","journal-title":"Eur. Urol."},{"key":"10718_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/oncolo\/oyad322","volume":"29","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. The 5th kidney cancer research summit: research accelerating cures for renal cell carcinoma in 2023. Oncologist 29, 91\u201398 (2024).","journal-title":"Oncologist"},{"key":"10718_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. & Kaelin, W. G. Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519\u20131530 (2020).","journal-title":"Nat. Med."},{"key":"10718_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cancers14051259","volume":"14","author":"L Davis","year":"2022","unstructured":"Davis, L. et al. Targeting HIF-2\u03b1 in the tumor microenvironment: redefining the role of HIF-2\u03b1 for solid cancer therapy. Cancers 14, 1259 (2022).","journal-title":"Cancers"},{"key":"10718_CR10","unstructured":"US Food and Drug Administration. Welireg (Belzutifan): prescribing information. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215383s010s011lbl.pdf (2025)."},{"key":"10718_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2024.08.2338","volume":"35","author":"N Agarwal","year":"2024","unstructured":"Agarwal, N. et al. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann. Oncol. 35, 1148\u20131156 (2024).","journal-title":"Ann. Oncol."},{"key":"10718_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N. Engl. J. Med. 391, 710\u2013721 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10718_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802\u2013805 (2021).","journal-title":"Nat. Med."},{"key":"10718_CR14","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","volume":"62","author":"R Xu","year":"2019","unstructured":"Xu, R. et al. 3-[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876\u20136893 (2019).","journal-title":"J. Med. Chem."},{"key":"10718_CR15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/jcph.2459","volume":"64","author":"DD Marathe","year":"2024","unstructured":"Marathe, D. D. et al. Exposure-response analyses for belzutifan to inform dosing considerations and labeling. J. Clin. Pharmacol. 64, 1246\u20131258 (2024).","journal-title":"J. Clin. Pharmacol."},{"key":"10718_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793\u2013803 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10718_CR18","doi-asserted-by":"crossref","unstructured":"Elvidge, G. P. et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1\u03b1, HIF-2\u03b1, and other pathways. J. Biol. Chem. 281, 15215\u201315226 (2006).","DOI":"10.1074\/jbc.M511408200"},{"key":"10718_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"10718_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"10718_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"10718_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-022-00587-8","volume":"18","author":"CT Taylor","year":"2022","unstructured":"Taylor, C. T. & Scholz, C. C. The effect of HIF on metabolism and immunity. Nat. Rev. Nephrol. 18, 573\u2013587 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"10718_CR23","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404\u20132415 (2019).","journal-title":"Lancet"},{"key":"10718_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10718_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.7150\/jca.105713","volume":"16","author":"S Zou","year":"2025","unstructured":"Zou, S. et al. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: a SEER Database analysis. J. Cancer 16, 1591\u20131597 (2025).","journal-title":"J. Cancer"},{"key":"10718_CR26","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/oncolo\/oyae181.049","volume":"29","author":"M Ghasemi","year":"2024","unstructured":"Ghasemi, M. et al. 56 clinical pharmacokinetic\/pharmacodynamic (PK\/PD) relationship confirms best-in-class potential of casdatifan (AB521), a small molecule inhibitor of HIF-2\u03b1 being developed in renal cancer. Oncologist 29, S30\u2013S31 (2024).","journal-title":"Oncologist"},{"key":"10718_CR27","doi-asserted-by":"publisher","first-page":"A002","DOI":"10.1158\/1538-7445.KIDNEY23-A002","volume":"83","author":"D Piovesan","year":"2023","unstructured":"Piovesan, D. et al. Targeting hypoxia inducible factor (HIF)-2\u03b1 with AB521, a novel and potent small molecule HIF-2\u03b1 inhibitor, for the treatment of clear cell renal cell carcinoma. Cancer Res. 83, A002 (2023).","journal-title":"Cancer Res."},{"key":"10718_CR28","doi-asserted-by":"crossref","unstructured":"Schweickert, P. et al. 91 (PB079): AB521 (Casdatifan) potently and selectively inhibits hypoxia-inducible factor 2 alpha (HIF-2\u03b1) dependent pro-tumorigenic activity. Eur. J. Cancer 211 (suppl. 1), 114617 (2024).","DOI":"10.1016\/j.ejca.2024.114617"},{"key":"10718_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113434","volume":"196","author":"E Jonasch","year":"2024","unstructured":"Jonasch, E. et al. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur. J. Cancer 196, 113434 (2024).","journal-title":"Eur. J. Cancer"},{"key":"10718_CR30","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1200\/JCO.2024.42.16_suppl.4534","volume":"42","author":"MB Atkins","year":"2024","unstructured":"Atkins, M. B. et al. Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): subgroup analysis of the phase 2 LITESPARK-013 study. J. Clin. Oncol. 42, 4534 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng, D. Y. C. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141\u2013148 (2013).","journal-title":"Lancet Oncol."},{"key":"10718_CR32","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2025.43.16_suppl.4548","volume":"43","author":"D Maj","year":"2025","unstructured":"Maj, D. et al. Second-line outcomes in metastatic renal cell carcinoma: the role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy. J. Clin. Oncol. 43, 4548 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR33","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1111\/bph.70075","volume":"182","author":"PG Schweickert","year":"2025","unstructured":"Schweickert, P. G. et al. Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2\u03b1 dependent transcription. Br. J. Pharmacol. 182, 4147\u20134167 (2025).","journal-title":"Br. J. Pharmacol."},{"key":"10718_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/JCO.2026.44.7_suppl.545","volume":"44","author":"N Agarwal","year":"2026","unstructured":"Agarwal, N. et al. Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 44, 545 (2026).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13046-016-0298-y","volume":"35","author":"J Yang","year":"2016","unstructured":"Yang, J. et al. HIF-2\u03b1 promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J. Exp. Clin. Cancer Res. 35, 26 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10718_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 692\u2013706 (2024).","journal-title":"Ann. Oncol."},{"key":"10718_CR37","doi-asserted-by":"publisher","first-page":"114533","DOI":"10.1016\/j.ejca.2024.114533","volume":"211","author":"T Choueiri","year":"2024","unstructured":"Choueiri, T. et al. Casdatifan in patients (pts) with previously treated clear cell renal cell cancer (ccRCC) and other solid tumors; preliminary results from ARC- 20: a phase 1, open-label dose-escalation and expansion study. Eur. J. Cancer 211, 114533 (2024).","journal-title":"Eur. J. Cancer"},{"key":"10718_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.2025.43.5_suppl.441","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri, T. K. et al. Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. J. Clin. Oncol. 43, 441 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR39","doi-asserted-by":"crossref","unstructured":"Choueiri, T. et al. Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141). Oncologist 30, oyaf276.003 (2025).","DOI":"10.1093\/oncolo\/oyaf276.003"},{"key":"10718_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2026.44.7_suppl.493","volume":"44","author":"TK Choueiri","year":"2026","unstructured":"Choueiri, T. K. et al. Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2\u03b1 inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): results from ARC-20. J. Clin. Oncol. 44, 493 (2026).","journal-title":"J. Clin. Oncol."},{"key":"10718_CR41","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733\u20131741 (2020).","journal-title":"Nat. Med."}],"updated-by":[{"DOI":"10.1038\/s41586-026-10958-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10718-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:18:22Z","timestamp":1787138302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10718-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":41,"journal-issue":{"issue":"8128","published-print":{"date-parts":[[2026,8,20]]}},"alternative-id":["10718"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10718-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-026-10958-x","URL":"https:\/\/doi.org\/10.1038\/s41586-026-10958-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.K.C. reports institutional and\/or personal, paid and\/or unpaid support for research, advisory boards, consultancy and\/or honoraria past 10 years, ongoing or not, from Alkermes, Arcus Biosciences, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Bicycle Therapeutics, Calithera, Caris, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Janssen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan\/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others) and Xencor (outside the submitted work); reports institutional patents filed on molecular alterations and immunotherapy response\/toxicity, rare genitourinary cancers and ctDNA\/liquids biopsies; reports equity in Abalytics, CureResponse, Faron Pharma, InnDura Therapeutics, Osel, Pionyr, Precede Bio, Primium and Tempest; reports serving on committees for ACCRU, ASCO (BOD 6\/2024-), ESMO, GU steering committee, KidneyCan and NCCN; reports medical writing and editorial assistance support that may have been funded by communications companies in part; reports mentorship of several non-US citizens on research projects with potential funding (in part) from non-US sources\/foreign components; reports that the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter; reports support in part by the Dana-Farber\/Harvard Cancer Center Kidney SPORE (2P50CA101942\u221216) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund, Roger and Kathy Marino Fund for Research Acceleration, Frank Shaughnessy Kidney Cancer Research Fund and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute. J.M. has served as a consultant, advisor and\/or has received research funding or royalties from Arcus Biosciences, BioNTech, Corvus Pharmaceuticals, DynamiCure Biotechnology, Eisai, Exelixis, Genentech\/Roche, IMUGENE, Kalivir Immunotherapeutics, Merck, ModeX Therapeutics, Peloton Therapeutics, Replimune, Rubius Therapeutics, Seattle Genetics\/Astellas, SillaJen, Tizona Therapeutics, Tocagen, Trishula Therapeutics, Tubulis, UpToDate and Vyriad. A.P. has served as a consultant, advisor, speaker and\/or has received research funding or honoraria from 1200 Pharma, AADi, AbbVie, Alpine Immune Sciences, Ambrx, Amgen, Arcus Biosciences, Arcus Ventures, Astellas Pharma, Bayer, BioNTech, BioTheryX, Bolt Biotherapeutics, Bristol Myers Squibb, Carrick Therapeutics, Compugen, Corvus Pharmaceuticals, Daiichi Sankyo, Ensem, Exelixis, Five Prime Therapeutics, Fochon Pharmaceuticals, Forty Seven, Genentech, Gilead Sciences, HalioDx, IGM Biosciences, Infinity Pharmaceuticals, Institut de Recherches Internationales Servier, Ionova, Janssen, Klus Pharma, KSQ Therapeutics, Livzon, Lilly, Loxo, Loxo@Lilly, Merck, MOMA Therapeutics, Moderna Therapeutics, Nektar, NiKang Therapeutics, Novartis, Olema Oncology, Pfizer, Pieris Pharmaceuticals, Plexxikon, Pionyr, Prelude Therapeutics, Pyrotech Therapeutics, Quanta Therapeutics, Roche, Sanofi, Scorpion Therapeutics, Seagen, Silverback Therapeutics, Surface Oncology, Symphogen, Syndax, Texas Society of Clinical Oncology (TxSCO), Upsher-Smith, Vigeo Therapeutics and Vividion Therapeutics. A.D. has served as a consultant, advisor and\/or has received research funding, honoraria or other compensation from Alimera Sciences, AstraZeneca, Athos Therapeutics, Attica Sciences, AVEO, Bristol Myers Squibb, Daiichi Sankyo, Dyania Health, EMD Serono, Exelixis, Genentech\/Roche, Immunomedics\/Gilead, Infinity Pharmaceuticals, Janssen, Jounce Therapeutics, Kite\/Gilead, Lilly, Loxo\/Lilly, Merck, Merck Sharp & Dohme, Moderna Therapeutics, PACT Pharma, Pfizer, Proteas Bioanalytics, RADMETRIX, Roche\/Genentech, Seattle Genetics\/Astellas, Seagen and Urogen Pharma. B.I.R. has served as a consultant, advisor and\/or has received research funding, leadership roles or travel support from Adela, Arcus Biosciences, AstraZeneca\/MedImmune, AVEO, Bristol Myers Squibb, Eisai, Exelixis, Formedics, HiberCell, Janssen, Merck, Pfizer and Roche\/Genentech. S.Y.R. has served on an advisory board\/steering committee for Amgen, Astellas, AstraZeneca, BeOne, Bristol Myers Squibb,\u00a0Boehringer Ingelheim, Daiichi Sankyo, Indivumed, LG Biochem, MSD, Ono Pharmaceuticals and as an invited speaker for Amgen, AstraZeneca, Astellas, BeOne, Bristol Myers Squibb, Daiichi Sankyo, MSD and Ono Pharmaceuticals. J.L.L. has served as a consultant, advisor and\/or has received research funding, honoraria or stock ownership from Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, AstraZeneca\/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Daiichi Sankyo\/Astra Zeneca, Eutilex, GI Innovation, Janssen, Johnson & Johnson\/Janssen, Karyopharm Therapeutics, LG Chem, Loxo\/Lilly, Merck, Merck KGaA, MSD, Novartis, Oscotec, Pfizer, Roche\/Genentech, Seagen and Zymeworks. M.C.O. has served as a consultant, advisor, speaker and\/or has received research funding or travel support from Arcus Biosciences, Aravive, Astellas Medivation, AstraZeneca\/MedImmune, AVEO, Bristol Myers Squibb Foundation, Bristol Myers Squibb, Eisai, Exelixis, HiberCell, Merck, Pfizer and Surface Oncology. R.K. has served as a speaker for Pfizer and as an advisor for EMD Serono and Springworks Therapeutics. C.H. has served as a consultant, advisor, speaker and\/or has received research funding, travel support or stock ownership from Adcentrx, Astellas Pharma, AstraZeneca, Bayer, Dava Oncology, Dendreon, Exelixis, Fujifilm, Genentech, Hengrui Pharmaceutical, Janssen Oncology, Johnson & Johnson, Johnson & Johnson\/Janssen, Merck, MJH Life Sciences\/OncLive, OncLive\/MJH Life Sciences, Pfizer, Scholar Rock, Seagen, Shionogi and Taiho Oncology. Y.S. has served as a consultant, advisor and\/or has received honoraria or travel support from AVEO, Castle Biosciences and Immunocore. S.H.P. has served as a consultant, advisor and\/or has received honoraria or research funding from Janssen Oncology, Merck, Merck Sharp & Dohme, Ono Pharmaceutical and Pfizer. P.C.B. has served as a consultant, advisor, speaker and\/or has received research funding, honoraria or stock ownership from Astellas Medivation, AstraZeneca, AVEO, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Caris Life Sciences, Dendreon, Eisai, EMD Serono, Exelixis, Ipsen, Luminate Medical, Medscape, Merck, Novartis, Pfizer, Pfizer\/Astellas, Sumitomo and UroToday. B.A.M. reports personal fees from Arcus, grants and personal fees from Aveo, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from Bristol Myer Squibb, grants and personal fees from Daiichi, personal fees from Eisai, grants and personal fees from Exelixis, personal fees from Genmab, grants and personal fees from Gilead, personal fees from Hexagon, personal fees from Lilly and grants and personal fees from Pfizer outside the submitted work. R.R.M. has served as a consultant, advisor and\/or has received research funding or honoraria from Ambrx, Arcus Biosciences, Astellas Medivation, AstraZeneca, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, Myovant Sciences, NeoMorph, Novartis, Oncternal Therapeutics, Pfizer, Precede Bio, Sanofi, Seagen, Sorrento Therapeutics, Sumitomo Pharma Oncology, Tempus, Telix Pharmaceuticals, Vividion Therapeutics and Artera. P.F., J.C., M.E., H.C., B.W., Y.G., J.S., A.K., S.C., R.M. and O.K. are employees of Arcus Biosciences and may own stock and\/or stock options.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}